Adaptive Biotechnologies Corporation (ADPT)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
ADPT price, last 12 months
Key stats
- Previous close
- $29.57
- Open
- $29.96
- Day range
- $28.88 – $29.96
- 52-week range
- $12.00 – $29.96
- Volume
- 1.7M
- Avg volume (20 days)
- 2.2M
- Market cap
- $4.7B
Performance
Technicals and fundamentals
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $4.7B